Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Chunchun Chen; Jinhai Zhu; Chao Zhang; Lin Wang; Yulong Li; Mingnan Du

doi:10.12659/AJCR.943936

19 September 2024 : Case report China

Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Challenging differential diagnosis, Unusual or unexpected effect of treatment

Chunchun Chen^1ABCE, Jinhai Zhu^1BCDE*, Chao Zhang^1CDE, Lin Wang^1DE, Yulong Li^1BF, Mingnan Du^1BEF

DOI: 10.12659/AJCR.943936

Am J Case Rep 2024; 25:e943936

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 3. Evolution of the axillary lesions during neoadjuvant chemotherapy for a woman with hormonal receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-positive occult breast cancer with axillary metastases. Magnetic resonance imaging examinations were performed before neoadjuvant treatment (February 18, 2022), after the second treatment (April 20, 2022), and after the sixth treatment (July 13, 2022). The patient was treated with TCbHP (trastuzumab and pertuzumab combined with docetaxel and carboplatin). The red circles indicate the axillary lesions.

Back to the Article

Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Your Privacy